Eric Delaporte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3268374/publications.pdf

Version: 2024-02-01

360 papers 16,086 citations

65 h-index 30922 102 g-index

371 all docs

371 docs citations

371 times ranked

11209 citing authors

#	Article	IF	CITATIONS
1	Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1. Science, 2006, 313, 523-526.	12.6	723
2	Origin of the human malaria parasite Plasmodium falciparum in gorillas. Nature, 2010, 467, 420-425.	27.8	445
3	SIV infection in wild gorillas. Nature, 2006, 444, 164-164.	27.8	315
4	Antigenic conservation and immunogenicity of the HIV coreceptor binding site. Journal of Experimental Medicine, 2005, 201, 1407-1419.	8.5	296
5	Unprecedented Degree of Human Immunodeficiency Virus Type 1 (HIV-1) Group M Genetic Diversity in the Democratic Republic of Congo Suggests that the HIV-1 Pandemic Originated in Central Africa. Journal of Virology, 2000, 74, 10498-10507.	3 . 4	295
6	Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet, The, 2004, 364, 29-34.	13.7	271
7	Risk to Human Health from a Plethora of Simian Immunodeficiency Viruses in Primate Bushmeat. Emerging Infectious Diseases, 2002, 8, 451-457.	4.3	240
8	Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. Aids, 2006, 20, 1181-1189.	2.2	240
9	African great apes are natural hosts of multiple related malaria species, including <i>Plasmodium falciparum</i> . Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1458-1463.	7.1	229
10	The Senegalese government's highly active antiretroviral therapy initiative: an 18 -month follow-up study. Aids, 2002 , 16 , 1363 - 1370 .	2.2	225
11	Isolation and partial characterization of an HIV-related virus occurring naturally in chimpanzees in Gabon. Aids, 1989, 3, 625-630.	2.2	217
12	Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1. New England Journal of Medicine, 2019, 381, 816-826.	27.0	196
13	Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-Subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naive Patients. Journal of Clinical Microbiology, 2000, 38, 3919-3925.	3.9	169
14	African origin of the malaria parasite Plasmodium vivax. Nature Communications, 2014, 5, 3346.	12.8	167
15	Long-Term Benefits of Highly Active Antiretroviral Therapy in Senegalese HIV-1-Infected Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 14-17.	2.1	147
16	Classification of hepatitis C viruses based on phylogenetic analysis of the envelope 1 and nonstructural 5B regions and identification of five additional subtypes Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 10134-10138.	7.1	143
17	Origin of the HIV-1 group O epidemic in western lowland gorillas. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1343-52.	7.1	136
18	Geographical distribution of HIV-1 group O viruses in Africa. Aids, 1997, 11, 493-498.	2.2	135

#	Article	IF	Citations
19	Adherence to HAART and its principal determinants in a cohort of Senegalese adults. Aids, 2003, 17, \$103-\$108.	2.2	131
20	Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results. Infectious Diseases of Poverty, 2016, 5, 66.	3.7	125
21	Characterization of a Novel Simian Immunodeficiency Virus with a vpu Gene from Greater Spot-Nosed Monkeys (Cercopithecus nictitans) Provides New Insights into Simian/Human Immunodeficiency Virus Phylogeny. Journal of Virology, 2002, 76, 8298-8309.	3.4	124
22	New Simian Immunodeficiency Virus Infecting De Brazza's Monkeys (Cercopithecus neglectus): Evidence for a Cercopithecus Monkey Virus Clade. Journal of Virology, 2004, 78, 7748-7762.	3.4	121
23	Evidence for Differences in MT2 Cell Tropism According to Genetic Subtypes of HIV-1: Syncytium-Inducing Variants Seem Rare Among Subtype C HIV-1 Viruses. Journal of Acquired Immune Deficiency Syndromes, 1999, 20, 115-121.	0.3	119
24	Genetic diversity and phylogeographic clustering of SIVcpzPtt in wild chimpanzees in Cameroon. Virology, 2007, 368, 155-171.	2.4	118
25	Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks. Nature, 2021, 597, 539-543.	27.8	113
26	Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. , 1996 , 50 , $293-302$.		112
27	Dating the common ancestor of SIVcpz and HIVâ€1 group M and the origin of HIVâ€1 subtypes by using a new method to uncover clockâ€ike molecular evolution. FASEB Journal, 2001, 15, 276-278.	0.5	111
28	Genetic and Phylogenetic Analysis of <i>env</i> Subtypes G and H in Central Africa. AIDS Research and Human Retroviruses, 1994, 10, 877-879.	1.1	106
29	Presence of multiple non-B subtypes and divergent subtype B strains of HIV-1 in individuals infected after overseas deployment. Aids, 1997, 11, 43-51.	2.2	105
30	Genetic Subtypes of HIV Type 1 and HIV Type 2 Strains in Commercial Sex Workers from Bamako, Mali. AIDS Research and Human Retroviruses, 1998, 14, 51-58.	1.1	104
31	Characterization of a Novel Simian Immunodeficiency Virus from Guereza Colobus Monkeys (Colobus) Tj ETQq1 1 2001, 75, 857-866.	0.784314 3.4	ł rgBT /Ove 102
32	Most env and gag Subtype A HIV-1 Viruses Circulating in West and West Central Africa Are Similar to the Prototype AG Recombinant Virus IBNG. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 363-374.	2.1	100
33	Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions. Infection, Genetics and Evolution, 2010, 10, 386-396.	2.3	100
34	Characterization of a Highly Replicative Intergroup M/O Human Immunodeficiency Virus Type 1 Recombinant Isolated from a Cameroonian Patient. Journal of Virology, 1999, 73, 7368-7375.	3.4	99
35	Evaluation of Different RNA Extraction Methods and Storage Conditions of Dried Plasma or Blood Spots for Human Immunodeficiency Virus Type 1 RNA Quantification and PCR Amplification for Drug Resistance Testing. Journal of Clinical Microbiology, 2009, 47, 1107-1118.	3.9	98
36	Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). Journal of General Virology, 1994, 75, 2393-2398.	2.9	97

3

#	Article	IF	CITATIONS
37	Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study. Lancet Infectious Diseases, The, 2017, 17, 545-552.	9.1	96
38	Most env and gag Subtype A HIV-1 Viruses Circulating in West and West Central Africa Are Similar to the Prototype AG Recombinant Virus IBNG. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 363-374.	2.1	95
39	Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage. Virology, 2003, 310, 254-266.	2.4	95
40	Near-Full-Length Genome Sequencing of Divergent African HIV Type 1 Subtype F Viruses Leads to the Identification of a New HIV Type 1 Subtype Designated K. AIDS Research and Human Retroviruses, 2000, 16, 139-151.	1.1	88
41	Antibody prevalence against haemorrhagic fever viruses in randomized representative central African populations. Research in Virology, 1989, 140, 319-331.	0.7	87
42	PREVALENCE OF INTESTINAL PARASITES INCLUDING MICROSPORIDIA IN HUMAN IMMUNODEFICIENCY VIRUS–INFECTED ADULTS IN CAMEROON: A CROSS-SECTIONAL STUDY. American Journal of Tropical Medicine and Hygiene, 2006, 74, 162-164.	1.4	87
43	Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. Lancet HIV,the, 2020, 7, e677-e687.	4.7	86
44	Identification of a New Simian Immunodeficiency Virus Lineage with a vpu Gene Present among Different Cercopithecus Monkeys (C. mona, C. cephus, and C. nictitans) from Cameroon. Journal of Virology, 2003, 77, 12523-12534.	3.4	85
45	AIDS and Non-AIDS Morbidity and Mortality Across the Spectrum of CD4 Cell Counts in HIV-Infected Adults Before Starting Antiretroviral Therapy in CÃ′te d'Ivoire. Clinical Infectious Diseases, 2012, 54, 714-723.	5.8	84
46	Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infectious Diseases, The, 2011, 11, 825-833.	9.1	83
47	Extraordinary Heterogeneity of Virological Outcomes in Patients Receiving Highly Antiretroviral Therapy and Monitored With the World Health Organization Public Health Approach in Sub-Saharan Africa and Southeast Asia. Clinical Infectious Diseases, 2014, 58, 99-109.	5.8	83
48	Using human immunodeficiency virus type 1 sequences to infer historical features of the acquired immune deficiency syndrome epidemic and human immunodeficiency virus evolution. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 855-866.	4.0	82
49	Two New Human T-Lymphotropic Virus Type I Phylogenetic Subtypes in Seroindeterminates, a Mbuti Pygmy and a Gabonese, Have Closest Relatives among African STLV-I Strains. Virology, 1998, 246, 277-287.	2.4	80
50	Low retention of HIVâ€infected patients on antiretroviral therapy in 11 clinical centres in West Africa. Tropical Medicine and International Health, 2010, 15, 34-42.	2.3	80
51	Predominance of Subtype A and G HIV Type 1 in Nigeria, with Geographical Differences in Their Distribution. AIDS Research and Human Retroviruses, 2000, 16, 315-325.	1.1	79
52	Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. Aids, 2003, 17, 1017-1022.	2.2	79
53	Molecular Epidemiology of Simian Immunodeficiency Virus Infection in Wild-Living Gorillas. Journal of Virology, 2010, 84, 1464-1476.	3.4	78
54	Use of a generic polymerase chain reaction assay detecting human T-lymphotropic virus (HTLV) types I, II and divergent simian strains in the evaluation of individuals with indeterminate HTLV serology. Journal of Medical Virology, 1997, 52, 1-7.	5.0	77

#	Article	IF	CITATIONS
55	Hepatitis B, C seroprevalence and delta viruses in HIVâ€1 Senegalese patients at HAART initiation (retrospective study). Journal of Medical Virology, 2008, 80, 1332-1336.	5.0	76
56	Depressive symptoms among survivors of Ebola virus disease in Conakry (Guinea): preliminary results of the PostEboGui cohort. BMC Psychiatry, 2017, 17, 127.	2.6	75
57	Epidemiology of HTLV-i in gabon (western equatorial Africa). International Journal of Cancer, 1988, 42, 687-689.	5.1	73
58	Widespread Infection with Homologues of Human Parvoviruses B19, PARV4, and Human Bocavirus of Chimpanzees and Gorillas in the Wild. Journal of Virology, 2010, 84, 10289-10296.	3.4	73
59	Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in Côte d'Ivoire. Lancet, The, 1992, 340, 339-340.	13.7	72
60	Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in Cameroon. PLoS ONE, 2009, 4, e7702.	2.5	72
61	New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors: Table 1 Journal of Infectious Diseases, 2016, 214, 1475-1476.	4.0	70
62	Resistance to Antiretroviral Treatment in Gabon: Need for Implementation of Guidelines on Antiretroviral Therapy Use and HIV-1 Drug Resistance Monitoring in Developing Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 165-168.	2.1	68
63	Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV. Journal of Clinical Virology, 2020, 129, 104521.	3.1	68
64	High Diversity of HIV-1 Subtype F Strains in Central Africa. Virology, 1999, 259, 99-109.	2.4	67
65	Seroepidemiological survey of hepatitis C virus among commercial sex workers and pregnant women in Kinshasa, Democratic Republic of Congo. International Journal of Epidemiology, 2001, 30, 872-877.	1.9	67
66	Sequence Note: Identification of All HIV Type 1 Group M Subtypes in Senegal, a Country with Low and Stable Seroprevalence. AIDS Research and Human Retroviruses, 2000, 16, 603-609.	1.1	66
67	Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. Journal of Clinical Virology, 2006, 36, 43-49.	3.1	66
68	Evidence for continuing cross-species transmission of SIVsmm to humans. Aids, 2013, 27, 2488-2491.	2.2	66
69	Survey of Ebola Viruses in Frugivorous and Insectivorous Bats in Guinea, Cameroon, and the Democratic Republic of the Congo, 2015–2017. Emerging Infectious Diseases, 2018, 24, 2228-2240.	4.3	66
70	Mother-to-Child Transmission of Human T-Cell Lymphotropic Virus Types I and II (HTLV-I/II) in Gabon: A Prospective Follow-up of 4 Years. Journal of Acquired Immune Deficiency Syndromes, 1996, 12, 187-192.	0.3	66
71	Epidemiological and molecular characteristics of HIV infection in Gabon, 1986–1994. Aids, 1996, 10, 903-910.	2.2	65
72	Detection and Genetic Characterization of Enteroviruses Circulating among Wild Populations of Chimpanzees in Cameroon: Relationship with Human and Simian Enteroviruses. Journal of Virology, 2011, 85, 4480-4486.	3.4	65

#	Article	IF	CITATIONS
73	High rates of virological failure and drug resistance in perinatally HIVâ€1â€infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo. Journal of the International AIDS Society, 2016, 19, 20683.	3.0	64
74	Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12) Tj ETQq	0 _{4.7} 0 rgBT	/Qverlock
	e384-e392.		
75	Simian T-Cell Leukemia Virus (STLV) Infection in Wild Primate Populations in Cameroon: Evidence for Dual STLV Type 1 and Type 3 Infection in Agile Mangabeys (Cercocebus agilis). Journal of Virology, 2004, 78, 4700-4709.	3.4	62
76	Low Levels of Antiretroviralâ€Resistant HIV Infection in a Routine Clinic in Cameroon that Uses the World Health Organization (WHO) Public Health Approach to Monitor Antiretroviral Treatment and Adequacy with the WHO Recommendation for Secondâ€Line Treatment. Clinical Infectious Diseases, 2009, 48, 1318-1322.	5.8	62
77	Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. Aids, 2011, 25, 2183-2188.	2.2	62
78	Medical countermeasures during the 2018 Ebola virus disease outbreak in the North Kivu and Ituri Provinces of the Democratic Republic of the Congo: a rapid genomic assessment. Lancet Infectious Diseases, The, 2019, 19, 648-657.	9.1	62
79	Distribution of HIV-1 Variants in the Democratic Republic of Congo Suggests Increase of Subtype C in Kinshasa Between 1997 and 2002. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 456-462.	2.1	61
80	Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping. Journal of Antimicrobial Chemotherapy, 2010, 65, 1562-1566.	3.0	60
81	Field Evaluation of Dried Blood Spots for Routine HIV-1 Viral Load and Drug Resistance Monitoring in Patients Receiving Antiretroviral Therapy in Africa and Asia. Journal of Clinical Microbiology, 2014, 52, 578-586.	3.9	60
82	Prevalence of HTLV-I and HTLV-II infection in gabon, africa: Comparison of the serological and pcr results. International Journal of Cancer, 1991, 49, 373-376.	5.1	59
83	No Difference in Clinical Progression between Patients Infected with the Predominant Human Immunodeficiency Virus Type 1 Circulating Recombinant Form (CRF) 02_AG Strain and Patients Not Infected with CRF02_AG, in Western and Westâ€Central Africa: A Fourâ€Year Prospective Multicenter Study. Journal of Infectious Diseases, 2002, 186, 486-492.	4.0	59
84	Lipodystrophy and Metabolic Disorders in HIV-1-Infected Adults on 4- to 9-Year Antiretroviral Therapy in Senegal: A Case-Control Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 224-230.	2.1	59
85	Characterization of a new simian immunodeficiency virus strain in a naturally infected Pan troglodytes troglodyteschimpanzee with AIDS related symptoms. Retrovirology, 2011, 8, 4.	2.0	58
86	Patterns of Resistance Mutations to Antiretroviral Drugs in Extensively Treated HIV-1–Infected Patients With Failure of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 36-43.	2.1	55
87	Ocular Complications in Survivors of the Ebola Outbreak in Guinea. American Journal of Ophthalmology, 2017, 175, 114-121.	3.3	55
88	<i>Plasmodium falciparum </i> -like parasites infecting wild apes in southern Cameroon do not represent a recurrent source of human malaria. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7020-7025.	7.1	53
89	Gorilla gorilla gorilla gut: a potential reservoir of pathogenic bacteria as revealed using culturomics and molecular tools. Scientific Reports, 2014, 4, 7174.	3.3	53
90	Isolation of Simian Immunodeficiency Viruses from Two Sooty Mangabeys in Côte d'Ivoire: Virological and Genetic Characterization and Relationship to Other HIV Type 2 and SIVsm/mac Strains. AIDS Research and Human Retroviruses, 1994, 10, 1289-1294.	1.1	52

#	Article	IF	Citations
91	Widely varying SIV prevalence rates in naturally infected primate species from Cameroon. Virology, 2006, 345, 174-189.	2.4	52
92	Virological failure rates and HIVâ€1 drug resistance patterns in patients on firstâ€line antiretroviral treatment in semirural and rural Gabon. Journal of the International AIDS Society, 2012, 15, 17985.	3.0	52
93	CRF06-cpx: A New Circulating Recombinant Form of HIV-1 in West Africa Involving Subtypes A, G, K, and J. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 522-530.	2.1	50
94	Prevalence of HIV and other sexually transmitted infections, and risk behaviours in unregistered sex workers in Dakar, Senegal. Aids, 2003, 17, 1811-1816.	2.2	50
95	Origin and diversity of human retroviruses. AIDS Reviews, 2014, 16, 23-34.	1.0	49
96	High level of hepatitis C endemicity in Gabon, equatorial Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 636-637.	1.8	47
97	Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus. Journal of Clinical Microbiology, 2017, 55, 165-176.	3.9	47
98	HIV-1 Drug-Resistance Mutations among Newly Diagnosed Patients before Scaling-Up Programmes in Burkina Faso and Cameroon. Antiviral Therapy, 2006, 11, 575-579.	1.0	47
99	HIV-1 subtypes and recombinants in the Republic of Congo. Infection, Genetics and Evolution, 2006, 6, 337-343.	2.3	46
100	Cryptococcal Antigen Screening in Asymptomatic HIV-Infected Antiretroviral Na \tilde{A} -ve Patients in Cameroon and Evaluation of the New Semi-Quantitative Biosynex CryptoPS Test. Frontiers in Microbiology, 2018, 9, 409.	3.5	46
101	HIV-1 superinfections in a cohort of commercial sex workers in Burkina Faso as assessed by an autologous heteroduplex mobility procedure. Aids, 2004, 18, 1645-1651.	2.2	45
102	HIV Type 1polGene Diversity and Antiretroviral Drug Resistance Mutations in the Democratic Republic of Congo (DRC). AIDS Research and Human Retroviruses, 2006, 22, 202-206.	1.1	45
103	Identification and molecular characterization of new STLV-1 and STLV-3 strains in wild-caught nonhuman primates in Cameroon. Virology, 2008, 371, 405-417.	2.4	45
104	High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lom \tilde{A} \mathbb{Q} , Togo. Journal of the International AIDS Society, 2011, 14, 30.	3.0	45
105	Prevalence of intestinal parasites including microsporidia in human immunodeficiency virus-infected adults in Cameroon: a cross-sectional study. American Journal of Tropical Medicine and Hygiene, 2006, 74, 162-4.	1.4	45
106	Patterns of adherence to antiretroviral therapy and <scp>HIV</scp> drug resistance over time in the <scp>S</scp> trial in <scp>C</scp> ameroon. HIV Medicine, 2014, 15, 478-487.	2.2	44
107	Intestinal Parasitic Infections in HIV-Infected Patients, Lao People's Democratic Republic. PLoS ONE, 2014, 9, e91452.	2.5	44
108	Full-length sequence analysis of SIVmus in wild populations of mustached monkeys (Cercopithecus) Tj ETQq0 0 407-418.	0 rgBT /Ον 2.4	verlock 10 Tf 5 43

407-418.

#	Article	IF	Citations
109	HTLV-II among Pygmies from Cameroon. AIDS Research and Human Retroviruses, 1993, 9, 707-707.	1.1	42
110	Partial Molecular Characterization of Two Simian Immunodeficiency Viruses (SIV) from African Colobids: SIVwrc from Western Red Colobus (Piliocolobus badius) and SIVolc from Olive Colobus () Tj ETQq0 0	0 r g:B T /O	ver ko ck 10 Tf
111	Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antiviral Therapy, 2009, 14, 401-411.	1.0	42
112	High prevalence of anti-hepatitis C virus antibodies in a Cameroon rural forest area. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 53-54.	1.8	41
113	Evaluation of Two Commercial Kits for the Detection of Genotypic Drug Resistance on a Panel of HIV Type 1 Subtypes A Through J. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 254-258.	2.1	41
114	Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. FEMS Immunology and Medical Microbiology, 2006, 46, 53-62.	2.7	41
115	Diabetes and Hypertension among Patients Receiving Antiretroviral Treatment Since 1998 in Senegal: Prevalence and Associated Factors. Isrn Aids, 2012, 2012, 1-8.	2.5	41
116	Identification of a New Circulating Recombinant Form of HIV Type 1, CRF11-cpx, Involving Subtypes A, G, J, and CRF01-AE, in Central Africa. AIDS Research and Human Retroviruses, 2002, 18, 231-236.	1.1	40
117	Comparison of Drug Resistance Mutations and Their Interpretation in Patients Infected With Non-B HIV-1 Variants and Matched Patients Infected With HIV-1 Subtype B. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 329-336.	2.1	40
118	Low Prevalence of HIV Type 1 Drug Resistance Mutations in Untreated, Recently Infected Patients from Burkina Faso, CÃ'te d'Ivoire, Senegal, Thailand, and Vietnam: The ANRS 12134 Study. AIDS Research and Human Retroviruses, 2009, 25, 1193-1196.	1.1	40
119	Field Assessment of Generic Antiretroviral Drugs: A Prospective Cohort Study in Cameroon. Antiviral Therapy, 2005, 10, 335-341.	1.0	40
120	Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. Aids, 2003, 17, S31-S38.	2.2	39
121	High Genetic Diversity of HIV-1 Strains in Chad, West Central Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 239-246.	2.1	39
122	Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infectious Diseases, The, 2013, 13, 577-586.	9.1	39
123	Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa. Aids, 2015, 29, 1473-1481.	2.2	39
124	Rapid Confirmation of the Zaire Ebola Virus in the Outbreak of the Equateur Province in the Democratic Republic of Congo: Implications for Public Health Interventions. Clinical Infectious Diseases, 2019, 68, 330-333.	5 . 8	39
125	Quality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal. HIV Medicine, 2007, 8, 92-95.	2.2	38
126	Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays. Clinical Microbiology and Infection, 2010, 16, 1525-1531.	6.0	38

#	Article	IF	Citations
127	Prevalence of gastrointestinal parasites in primate bushmeat and pets in Cameroon. Veterinary Parasitology, 2011, 175, 187-191.	1.8	38
128	Sequence Note The Identification of a Complex A/G/I/J Recombinant HIV Type 1 Virus in Various West African Countries. AIDS Research and Human Retroviruses, 1999, 15, 1707-1712.	1.1	37
129	Access to antiretroviral drugs and AIDS management in Senegal. Aids, 2003, 17, S95-S101.	2.2	37
130	Antiretroviral Therapy in Public and Private Routine Health Care Clinics in Cameroon: Lessons from the Douala Antiretroviral (DARVIR) Initiative. Clinical Infectious Diseases, 2005, 41, 108-111.	5.8	37
131	Gender Differences in Adherence and Response to Antiretroviral Treatment in the Stratall Trial in Rural District Hospitals in Cameroon. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 355-364.	2.1	37
132	Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa. Aids, 2012, 26, 951-957.	2.2	36
133	Risk of Virological Failure and Drug Resistance During First and Second-Line Antiretroviral Therapy in a 10-Year Cohort in Senegal. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 381-387.	2.1	36
134	Prevalence of infection among asymptomatic and paucisymptomatic contact persons exposed to Ebola virus in Guinea: a retrospective, cross-sectional observational study. Lancet Infectious Diseases, The, 2019, 19, 308-316.	9.1	36
135	A 84â€month follow up of adherence to HAART in a cohort of adult Senegalese patients. Tropical Medicine and International Health, 2007, 12, 1191-1198.	2.3	35
136	Detection of Termites and Other Insects Consumed by African Great Apes using Molecular Fecal Analysis. Scientific Reports, 2014, 4, 4478.	3.3	35
137	Integration of genomic sequencing into the response to the Ebola virus outbreak in Nord Kivu, Democratic Republic of the Congo. Nature Medicine, 2021, 27, 710-716.	30.7	35
138	Identification of a ComplexenvSubtype E HIV Type 1 Virus from the Democratic Republic of Congo, Recombinant with A, G, H, J, K, and Unknown Subtypes. AIDS Research and Human Retroviruses, 2000, 16, 2059-2064.	1.1	34
139	Seroprevalence of HIV-1, HIV-2, and HIV-1 Group O in Nigeria: Evidence for a Growing Increase of HIV Infection. Journal of Acquired Immune Deficiency Syndromes, 1997, 16, 204-210.	0.3	34
140	Revisiting Long-Term Adherence to Highly Active Antiretroviral Therapy in Senegal Using Latent Class Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 55-61.	2.1	33
141	Co-circulation of enteroviruses between apes and humans. Journal of General Virology, 2014, 95, 403-407.	2.9	33
142	Long-lasting severe immune dysfunction in Ebola virus disease survivors. Nature Communications, 2020, 11, 3730.	12.8	33
143	Interpatient genetic variability of HIV-1 group O. Aids, 1999, 13, 41-48.	2,2	33
144	Molecular Evidence for the Presence of Rickettsia Felis in the Feces of Wild-living African Apes. PLoS ONE, 2013, 8, e54679.	2.5	33

#	Article	IF	CITATIONS
145	Further evidence of the presence of genetically aberrant HIV-1 strains in Cameroon and Gabon. Aids, 1994, 8, 1012.	2.2	32
146	Predominance of CRF02-AG and CRF06-cpx in Niger, West Africa. AIDS Research and Human Retroviruses, 2002, 18, 723-726.	1.1	32
147	Evaluation of Four Simple/Rapid Assays and Two Fourth-Generation ELISAs for the Identification of HIV Infection on a Serum Panel Representing the HIV-1 Group M Genetic Diversity in Cameroon. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1632-1640.	2.1	32
148	Tolerability and Effectiveness of First-Line Regimens Combining Nevirapine and Lamivudine Plus Zidovudine or Stavudine in Cameroon. AIDS Research and Human Retroviruses, 2008, 24, 393-400.	1.1	32
149	High HIV Type 1 Group M <i>pol</i> Diversity and Low Rate of Antiretroviral Resistance Mutations Among the Uniformed Services in Kinshasa, Democratic Republic of the Congo. AIDS Research and Human Retroviruses, 2011, 27, 323-329.	1.1	32
150	Virological outcome and patterns of HIVâ€1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon. Journal of the International AIDS Society, 2013, 16, 18004.	3.0	32
151	First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the leDEA West Africa collaboration. Aids, 2010, 24, 1043-1050.	2.2	31
152	High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy. HIV Medicine, 2010, 11, 85-89.	2.2	31
153	Lamivudine-Resistant HBV Infection in HIV-Positive Patients Receiving Antiretroviral Therapy in a Public Routine Clinic in Cameroon. Antiviral Therapy, 2012, 17, 321-326.	1.0	31
154	Impact of variability in adherence to HIV antiretroviral therapy on the immunovirological response and mortality. BMC Medical Research Methodology, 2015, 15, 10.	3.1	31
155	Evidence of stable HIV seroprevalences in selected populations in the Democratic Republic of the Congo. Aids, 1998, 12, 905-910.	2.2	30
156	Prevalence and risk factors of cervicovaginal HIV shedding among HIV-1 and HIV-2 infected women in Dakar, Senegal. Sexually Transmitted Infections, 2001, 77, 190-193.	1.9	30
157	Full-Length Genome Characterization of a Novel Simian Immunodeficiency Virus Lineage (SIVolc) from Olive Colobus (Procolobus verus) and New SIVwrcPbb Strains from Western Red Colobus (Piliocolobus badius badius) from the Tail`Forest in Ivory Coast. Journal of Virology, 2009, 83, 428-439.	3.4	30
158	Adherence to Antiretroviral Treatment in HIV-Positive Patients in the Cameroon Context: Promoting the Use of Medication Reminder Methods. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S40-S43.	2.1	30
159	Simian retroviruses in African apes. Clinical Microbiology and Infection, 2012, 18, 514-520.	6.0	30
160	Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine. Aids, 2007, 21, 768-771.	2.2	29
161	Novel Multiplexed HIV/Simian Immunodeficiency Virus Antibody Detection Assay. Emerging Infectious Diseases, 2011, 17, 2277-2286.	4.3	29
162	Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. Journal of Antimicrobial Chemotherapy, 2013, 68, 1400-1405.	3.0	29

#	Article	lF	Citations
163	Changes in the Renal Function After Tenofovir-Containing Antiretroviral Therapy Initiation in a Senegalese Cohort (ANRS 1215). AIDS Research and Human Retroviruses, 2010, 26, 1221-1227.	1.1	28
164	Resistance to Antiretroviral Drugs in Treated and Drug-Naive Patients in the Democratic Republic of Congo. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S27-S33.	2.1	28
165	Factors associated with late antiretroviral therapy initiation in Cameroon: a representative multilevel analysis. Journal of Antimicrobial Chemotherapy, 2013, 68, 1388-1399.	3.0	28
166	Short Communication: High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa. AIDS Research and Human Retroviruses, 2016, 32, 1159-1162.	1,1	28
167	Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antiviral Therapy, 2009, 14, 401-11.	1.0	28
168	Identification and Molecular Characterization of Subsubtype A4 in Central Africa. AIDS Research and Human Retroviruses, 2006, 22, 182-187.	1.1	27
169	Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health, 2010, 10, 105.	2.9	27
170	High Failure Rate of the ViroSeq HIV-1 Genotyping System for Drug Resistance Testing in Cameroon, a Country with Broad HIV-1 Genetic Diversity. Journal of Clinical Microbiology, 2011, 49, 1635-1641.	3.9	27
171	2018 Ebola virus disease outbreak in \tilde{A} % quateur Province, Democratic Republic of the Congo: a retrospective genomic characterisation. Lancet Infectious Diseases, The, 2019, 19, 641-647.	9.1	27
172	Human T-Cell leukemia virus type I isolates from Gabon and Ghana: Comparative analysis of proviral genomes. Virology, 1987, 161, 315-320.	2.4	26
173	Genetic Characterization of the nef Gene from Human Immunodeficiency Virus Type 1 Group M Strains Representing Genetic Subtypes A, B, C, E, F, G, and H. AIDS Research and Human Retroviruses, 1999, 15, 23-32.	1.1	26
174	Evidence for a Second Simian T-Cell Lymphotropic Virus Type 3 in Cercopithecus nictitans from Cameroon. Journal of Virology, 2001, 75, 11939-11941.	3.4	26
175	Noninvasive Follow-Up of Simian Immunodeficiency Virus Infection in Wild-Living Nonhabituated Western Lowland Gorillas in Cameroon. Journal of Virology, 2012, 86, 9760-9772.	3.4	26
176	Task Shifting HIV Care in Rural District Hospitals in Cameroon. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 569-576.	2.1	26
177	Investigation of minor species <i>Candida africana, Candida stellatoidea</i> and <i>Candida dubliniensis</i> in the <i>Candida albicans</i> complex among Yaoundé (Cameroon) <scp>HIV</scp> â€infected patients. Mycoses, 2015, 58, 33-39.	4.0	26
178	A 40 months follow-up of Ebola virus disease survivors in Guinea (Postebogui)Âreveals longterm detection of Ebola viral RNA in semen and breast milk. Open Forum Infectious Diseases, 2019, 6, ofz482.	0.9	26
179	Prevalence and transmission of simian immunodeficiency virus and simian T-cell leukemia virus in a semi-free-range breeding colony of mandrills in Gabon. Aids, 1991, 5, 1385.	2.2	25
180	Demographic Factors Associated with HTLV-1 Infection in a Gabonese Community. International Journal of Epidemiology, 1994, 23, 812-817.	1.9	25

#	Article	IF	Citations
181	Emergence of Complex and Diverse CRF02-AG/CRF06-cpx Recombinant HIV Type 1 Strains in Niger, West Africa. AIDS Research and Human Retroviruses, 2003, 19, 77-82.	1.1	25
182	Antiretroviral Drug Resistance and Routine Therapy, Cameroon. Emerging Infectious Diseases, 2006, 12, 1001-1004.	4.3	25
183	Phylogenetic Analysis of Brazilian HIV Type 1 Subtype D Strains: Tracing the Origin of This Subtype in Brazil. AIDS Research and Human Retroviruses, 2006, 22, 207-211.	1.1	25
184	Prevalence and genetic diversity of simian immunodeficiency virus infection in wild-living red colobus monkeys (Piliocolobus badius badius) from the TaÃ⁻ forest, Cà te d'lvoire. Infection, Genetics and Evolution, 2008, 8, 1-14.	2.3	25
185	Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings. Expert Opinion on Drug Safety, 2008, 7, 283-293.	2.4	25
186	Adherence to Antiretroviral Therapy Assessed by Drug Level Monitoring and Self-Report in Cameroon. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 216-219.	2.1	25
187	Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients. Clinical Microbiology and Infection, 2013, 19, 763-769.	6.0	25
188	Wild Gorillas as a Potential Reservoir of <i>Leishmania major </i> . Journal of Infectious Diseases, 2015, 211, 267-273.	4.0	25
189	Humoral responses against the 85A and 85B antigens of Mycobacterium bovis BCG in patients with leprosy and tuberculosis. Journal of Clinical Microbiology, 1992, 30, 1608-1610.	3.9	25
190	Political and socioeconomic instability. Aids, 2004, 18, 832-834.	2.2	24
191	Molecular epidemiological tracing of HIV-1 outbreaks in Hainan island of southern China. Aids, 2009, 23, 977-985.	2.2	24
192	Assessment of gastrointestinal parasites in wild chimpanzees (Pan troglodytes troglodytes) in southeast Cameroon. Parasitology Research, 2014, 113, 2541-2550.	1.6	24
193	In-depth analysis of HIV-1 drug resistance mutations in HIV-infected individuals failing first-line regimens in West and Central Africa. Aids, 2016, 30, 2577-2589.	2.2	24
194	Age-related prevalence of antibody response against three different, defined Plasmodium falciparum antigens in children from the Haut-Ogooué province in Gabon. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1989, 83, 147-151.	1.8	23
195	Short Communication: Molecular Characterization of the Envelope Transmembrane Glycoprotein of 13 New Human Immunodeficiency Virus Type 1 Group O Strains from Six Different African Countries. AIDS Research and Human Retroviruses, 1998, 14, 1281-1285.	1.1	23
196	Full molecular characterization of a simian immunodeficiency virus, SIVwrcpbt from Temminck's red colobus (Piliocolobus badius temminckii) from Abuko Nature Reserve, The Gambia. Virology, 2008, 376, 90-100.	2.4	23
197	Identification and Molecular Characterization of New Simian T Cell Lymphotropic Viruses in Nonhuman Primates Bushmeat from the Democratic Republic of Congo. AIDS Research and Human Retroviruses, 2012, 28, 628-635.	1.1	23
198	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, e9-e15.	2.1	23

#	Article	IF	Citations
199	Comparison of different nucleic acid preparation methods to improve specific HIV-1 RNA isolation for viral load testing on dried blood spots. Journal of Virological Methods, 2018, 251, 75-79.	2.1	23
200	Extensive Serological Survey of Multiple African Nonhuman Primate Species Reveals Low Prevalence of Immunoglobulin G Antibodies to 4 Ebola Virus Species. Journal of Infectious Diseases, 2019, 220, 1599-1608.	4.0	23
201	HTLV-I Infection Among Prostitutes and Pregnant Women in Kinshasa, ZaÃ-re. Journal of Acquired Immune Deficiency Syndromes, 1995, 8, 511-515.	0.3	22
202	Genetic Characterization of Accessory Genes from Human Immunodeficiency Virus Type 1 Group O Strains. AIDS Research and Human Retroviruses, $1998,14,951$ - $961.$	1.1	22
203	Complete Genome Analysis of One of the Earliest SIVcpzPtt Strains from Gabon (SIVcpzGAB2). AIDS Research and Human Retroviruses, 2004, 20, 1377-1381.	1.1	22
204	Enfuvirtide Binding Domain Is Highly Conserved in Non-B HIV Type 1 Strains from Cameroon, West Central Africa. AIDS Research and Human Retroviruses, 2005, 21, 430-433.	1.1	22
205	Long-Term Efficacy and Tolerance of Efavirenz- and Nevirapine-Containing Regimens in Adult HIV Type 1 Senegalese Patients. AIDS Research and Human Retroviruses, 2008, 24, 753-760.	1.1	22
206	Molecular Tracing of Sexual HIV Type 1 Transmission in the Southwest Border of China. AIDS Research and Human Retroviruses, 2008, 24, 733-742.	1.1	22
207	Cryptoccocal meningitis in YaoundÃ $ \odot $ (Cameroon) HIV infected patients: Diagnosis, frequency and Cryptococcus neoformans isolates susceptibility study to fluconazole. Journal De Mycologie Medicale, 2015, 25, 11-16.	1.5	22
208	HIV-1 group O infection in Cameroon from 2006 to 2013: Prevalence, genetic diversity, evolution and public health challenges. Infection, Genetics and Evolution, 2015, 36, 210-216.	2.3	22
209	Dynamics of Ebola RNA Persistence in Semen: A Report From the Postebogui Cohort in Guinea. Clinical Infectious Diseases, 2017, 64, 1788-1790.	5.8	22
210	Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting. BMC Nephrology, 2019, 20, 155.	1.8	22
211	CRF06-cpx is the predominant HIV-1 variant in AIDS patients from Ouagadougou, the capital city of Burkina Faso. Aids, 2003, 17, 441-442.	2.2	22
212	V3 Serotyping of HIV-1 Infection: Correlation With Genotyping and Limitations. Journal of Acquired Immune Deficiency Syndromes, 1999, 20, 432-441.	0.3	21
213	Molecular characterization of a novel simian immunodeficiency virus lineage (SIVtal) from northern talapoins (Miopithecus ogouensis). Virology, 2006, 349, 55-65.	2.4	21
214	HIV Type 1 Diversity and Antiretroviral Drug Resistance Mutations in Burundi. AIDS Research and Human Retroviruses, 2007, 23, 175-180.	1.1	21
215	Genetic Characterization of Eight Full-Length HIV Type 1 Genomes from the Democratic Republic of Congo (DRC) Reveal a New Subsubtype, A5, in the A Radiation That Predominates in the Recombinant Structure of CRF26_A5U. AIDS Research and Human Retroviruses, 2009, 25, 823-832.	1.1	21
216	Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patientsa ⁻ †. Infection, Genetics and Evolution, 2009, 9, 646-652.	2.3	21

#	Article	IF	CITATIONS
217	Molecular Epidemiology of Human Immunodeficiency Virus Type 1 in Guangdong Province of Southern China. PLoS ONE, 2012, 7, e48747.	2.5	21
218	Successful Integrase Inhibitor-Based Highly Active Antiretroviral Therapy for a Multidrug-Class-Resistant HIV Type 1 Group O-Infected Patient in Cameroon. AIDS Research and Human Retroviruses, 2013, 29, 1-3.	1.1	21
219	Absence of a Relationship between Antibodies to Hepatitis C Virus and Hepatocellular Carcinoma in Mozambique. American Journal of Tropical Medicine and Hygiene, 1993, 48, 237-242.	1.4	21
220	Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort. BMC Infectious Diseases, 2010, 10, 179.	2.9	20
221	Time Patterns of Adherence and Long-Term Virological Response to Non-Nucleoside Reverse Transcriptase Inhibitor Regimens in the Stratall Anrs 12110/Esther Trial in Cameroon. Antiviral Therapy, 2013, 18, 29-37.	1.0	20
222	Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study. PLoS Neglected Tropical Diseases, 2019, 13, e0007812.	3.0	20
223	Wide Diversity of Coronaviruses in Frugivorous and Insectivorous Bat Species: A Pilot Study in Guinea, West Africa. Viruses, 2020, 12, 855.	3.3	20
224	HIV and Hepatitis C Virus Coinfection, Cameroon. Emerging Infectious Diseases, 2007, 13, 514-516.	4.3	19
225	Reduced Quantitative Ultrasound Bone Mineral Density in HIV-Infected Patients on Antiretroviral Therapy in Senegal. PLoS ONE, 2012, 7, e31726.	2.5	19
226	Evaluation of Two Techniques for Viral Load Monitoring Using Dried Blood Spot in Routine Practice in Vietnam (French National Agency for AIDS and Hepatitis Research 12338). Open Forum Infectious Diseases, 2016, 3, ofw142.	0.9	19
227	Molecular epidemiology reveals genetic diversity among 363 isolates of the ⟨i⟩Cryptococcus neoformans⟨ i⟩ and ⟨i⟩Cryptococcus gattii⟨ i⟩ species complex in 61 Ivorian ⟨scp⟩HIV⟨ scp⟩â€positive patients. Mycoses, 2016, 59, 811-817.	4.0	19
228	Role of Wildlife in Emergence of Ebola Virus in Kaigbono (Likati), Democratic Republic of the Congo, 2017. Emerging Infectious Diseases, 2020, 26, 2205-2209.	4.3	19
229	Genetic and Antigenic Variability of HIV Type 1 in Brazil. AIDS Research and Human Retroviruses, 1994, 10, 1157-1163.	1.1	18
230	Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions. Aids, 1994, 8, 1657-1662.	2.2	18
231	Ubiquitous Hepatocystis infections, but no evidence of Plasmodium falciparum-like malaria parasites in wild greater spot-nosed monkeys (Cercopithecus nictitans). International Journal for Parasitology, 2012, 42, 709-713.	3.1	18
232	Nonhuman primate retroviruses from Cambodia: High simian foamy virus prevalence, identification of divergent STLV-1 strains and no evidence of SIV infection. Infection, Genetics and Evolution, 2013, 18, 325-334.	2.3	18
233	Multiplex detection of antibodies to Chikungunya, O'nyong-nyong, Zika, Dengue, West Nile and Usutu viruses in diverse non-human primate species from Cameroon and the Democratic Republic of Congo. PLoS Neglected Tropical Diseases, 2021, 15, e0009028.	3.0	18
234	Congenital hydrocephalus due to intrauterine HTLV-I infection. Lancet, The, 1991, 337, 248.	13.7	17

#	Article	IF	CITATIONS
235	Non-contiguous finished genome sequence and description of Gorillibacterium massiliense gen. nov, sp. nov., a new member of the family Paenibacillaceae. Standards in Genomic Sciences, 2014, 9, 807-820.	1.5	17
236	Pathogenic Eukaryotes in Gut Microbiota of Western Lowland Gorillas as Revealed by Molecular Survey. Scientific Reports, 2014, 4, 6417.	3.3	17
237	Characteristics of the musculoskeletal symptoms observed among survivors of Ebola virus disease in the Postebogui cohort in Guinea. Rheumatology, 2017, 56, 2068-2072.	1.9	17
238	HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antiviral Therapy, 2006, 11, 575-9.	1.0	17
239	Hepatitis C in remote populations of southern Cameroon. Annals of Tropical Medicine and Parasitology, 1994, 88, 97-98.	1.6	16
240	Evidence for HIV-1 group O infection in Nigeria. Lancet, The, 1995, 346, 308.	13.7	16
241	Presence of CRF09_cpx and Complex CRF02_AG/CRF09_cpx Recombinant HIV Type 1 Strains in Côte d'Ivoire, West Africa. AIDS Research and Human Retroviruses, 2005, 21, 667-672.	1.1	16
242	Pharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Cote d'Ivoire. Pharmacoepidemiology and Drug Safety, 2011, 20, 1303-1310.	1.9	16
243	Use of RNAlater $\hat{A}^{\text{@}}$ as a preservation method for parasitic coprology studies in wild-living chimpanzees. Experimental Parasitology, 2013, 135, 257-261.	1.2	16
244	Alarming rates of virological failure and drug resistance in patients on long-term antiretroviral treatment in routine HIV clinics in Togo. Aids, 2015, 29, 2527-2530.	2.2	16
245	Virological success after 12 and 24 months of antiretroviral therapy in sub-Saharan Africa: Comparing results of trials, cohorts and cross-sectional studies using a systematic review and meta-analysis. PLoS ONE, 2017, 12, e0174767.	2.5	16
246	Advances in clinical trial design: Weaving tomorrow's TB treatments. PLoS Medicine, 2020, 17, e1003059.	8.4	16
247	Comparative typing analyses of clinical and environmental strains of the Cryptococcus neoformans/Cryptococcus gattii species complex from Ivory Coast. Journal of Medical Microbiology, 2018, 67, 87-96.	1.8	16
248	Treatment Regimens of STD Patients in Cameroon. Sexually Transmitted Diseases, 1994, 21, 124.	1.7	15
249	Commercial Logging and HIV Epidemic, Rural Equatorial Africa. Emerging Infectious Diseases, 2004, 10, 1953-1956.	4.3	15
250	Characterization of an Old Complex Circulating Recombinant Form, CRF27_cpx, Originating from the Democratic Republic of Congo (DRC) and Circulating in France. AIDS Research and Human Retroviruses, 2008, 24, 315-321.	1,1	15
251	High Rates of Infection with Novel Enterovirus Variants in Wild Populations of Mandrills and Other Old World Monkey Species. Journal of Virology, 2014, 88, 5967-5976.	3.4	15
252	Benefits of taskâ€shifting <scp>HIV</scp> care to nurses in terms of healthâ€related quality of life in patients initiating antiretroviral therapy in rural district hospitals in <scp>C</scp> ameroon [Stratall Agence Nationale de Recherche sur le <scp>SIDA</scp> (<scp>ANRS</scp>) 12110/Ensemble pour une Solidarité Thérapeutique HospitaliÃre en Réseau (<scp>ESTHER</scp>) substudy]. HIV Medicine, 2015, 16 307-318.	2.2	15

#	Article	IF	Citations
253	The fourth HIV epidemic. Lancet Infectious Diseases, The, 2018, 18, 379-380.	9.1	15
254	Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. Antiviral Therapy, 2005, 10, 335-41.	1.0	15
255	Interpretation of antibodies reacting solely with human retroviral core proteins in western equatorial Africa. Aids, 1989, 3, 179-182.	2.2	14
256	Mycobacterium ulcerans Associated with Infection Due to the Human Immunodeficiency Virus. Clinical Infectious Diseases, 1994, 18, 839-839.	5.8	14
257	Development and Evaluation of a DNA Enzyme Immunoassay Method for env Genotyping of Subtypes A through G of Human Immunodeficiency Virus Type 1 Group M, with Discrimination of the Circulating Recombinant Forms CRF01_AE and CRF02_AG. Journal of Clinical Microbiology, 2002, 40, 1010-1022.	3.9	14
258	High frequency of HIV-1 infections with multiple HIV-1 strains in men having sex with men (MSM) in Senegal. Infection, Genetics and Evolution, 2013, 20, 206-214.	2.3	14
259	High Rates of Drug Resistance Among Newly Diagnosed HIV-infected Children in the National Prevention of Mother-to-child Transmission Program in Togo. Pediatric Infectious Disease Journal, 2016, 35, 879-885.	2.0	14
260	First field evaluation of the optimized CE marked Abbott protocol for HIV RNA testing on dried blood spot in a routine clinical setting in Vietnam. PLoS ONE, 2018, 13, e0191920.	2.5	14
261	Non-hodgkin lymphoma in gabon and its relation to HTLV-I. International Journal of Cancer, 1993, 53, 48-50.	5.1	13
262	Tenofovir-Emtricitabine-Efavirenz in HIV-I-Infected Adults in Senegal: A 96-Week Pilot Trial in Treatment-Naive Patients. Journal of the International Association of Providers of AIDS Care, 2009, 8, 379-384.	1.2	13
263	Full-length genome sequence of a simian immunodeficiency virus (SIV) infecting a captive agile mangabey (Cercocebus agilis) is closely related to SIVrcm infecting wild red-capped mangabeys (Cercocebus torquatus) in Cameroon. Journal of General Virology, 2010, 91, 2959-2964.	2.9	13
264	Evaluation of Four Tenofovir-Containing Regimens as First-Line Treatments in Cameroon and Senegal: The Anrs 12115 Dayana Trial. Antiviral Therapy, 2014, 19, 51-59.	1.0	13
265	High Prevalences and a Wide Genetic Diversity of Simian Retroviruses in Non-human Primate Bushmeat in Rural Areas of the Democratic Republic of Congo. EcoHealth, 2017, 14, 100-114.	2.0	13
266	Investigating the Circulation of Ebola Viruses in Bats during the Ebola Virus Disease Outbreaks in the Equateur and North Kivu Provinces of the Democratic Republic of Congo from 2018. Pathogens, 2021, 10, 557.	2.8	13
267	Complete nucleotide sequence of an African human T-lymphotropic virus type II subtype b isolate (HTLV-II-Gab): molecular and phylogenetic analysis Journal of General Virology, 1998, 79, 269-277.	2.9	13
268	Prevalence and genetic variants of hepatitis GB-C/HG and TT viruses in Gabon, equatorial Africa American Journal of Tropical Medicine and Hygiene, 2000, 63, 192-198.	1.4	13
269	Population-based study of serum hepatitis B virus DNA in Gabon. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 539-540.	1.8	12
270	Clinical algorithms for the screening of pregnant women for STDs in Libreville, Gabon: which alternatives?. Sexually Transmitted Infections, 1998, 74, 35-39.	1.9	12

#	Article	IF	CITATIONS
271	Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. Antiviral Therapy, 2010, 15, 1039-1043.	1.0	12
272	Virologic Failure and Human Immunodeficiency Virus Drug Resistance in Rural Cameroon With Regard to the UNAIDS 90-90-90 Treatment Targets. Open Forum Infectious Diseases, 2016, 3, ofw233.	0.9	12
273	Extraordinary long-term and fluctuating persistence of Ebola virus RNA in semen of survivors in Guinea: implications for public health. Clinical Microbiology and Infection, 2017, 23, 412-413.	6.0	12
274	Treatment interruption in <scp>HIV</scp> â€positive patients followed up in Cameroon's antiretroviral treatment programme: individual and health care supplyâ€related factors (<scp>ANRS</scp> â€12288) Tj ETQq0	0 23 3gBT/	O ve rlock 10
275	Understanding Long-term Evolution and Predictors of Sequelae of Ebola Virus Disease Survivors in Guinea: A 48-Month Prospective, Longitudinal Cohort Study (PostEboGui). Clinical Infectious Diseases, 2021, 73, 2166-2174.	5.8	12
276	Low rate of hepatitis C virus antibodies in blood donors and pregnant women from Niger. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86, 553.	1.8	11
277	Rapid spread of HIV infections in Abidjan, Ivory Coast, 1987–1990. European Journal of Clinical Microbiology and Infectious Diseases, 1992, 11, 271-273.	2.9	11
278	Full-Length Genome Sequencing of HIV Type 1 Group O Viruses Isolated from a Heterosexual Transmission Cluster in Senegal. AIDS Research and Human Retroviruses, 2001, 17, 1211-1216.	1.1	11
279	Change over time of mortality predictors after HAART initiation in a Senegalese cohort. European Journal of Epidemiology, 2008, 23, 227-234.	5.7	11
280	DIAGNOSTIC APPROACHES TO IMPORTED SCHISTOSOMAL MYELORADICULOPATHY IN TRAVELERS. Neurology, 2008, 71, 66-67.	1.1	11
281	CD4-Specific Mortality Rates Among HIV-Infected Adults With High CD4 Counts and No Antiretroviral Treatment in West Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 213-219.	2.1	11
282	Full-Length Genome Analyses of Two New Simian Immunodeficiency Virus (SIV) Strains from Mustached Monkeys (C. Cephus) in Gabon Illustrate a Complex Evolutionary History among the SIVmus/mon/gsn Lineage. Viruses, 2014, 6, 2880-2898.	3.3	11
283	Differentiation between HIV-1 and HIV-2 infection by radioimmunoprecipitation and synthetic peptides in double reactive sera. Aids, 1989, 3, 401.	2.2	10
284	Short and Long-Term Incidence of Tuberculosis and CD4-Cell Count Dynamic on HAART in Senegal. Open AIDS Journal, 2009, 3, 63-70.	0.5	10
285	CRF45_AKU, a Circulating Recombinant from Central Africa, Is Probably the Common Ancestor of HIV Type 1 MAL and HIV Type 1 NOGIL. AIDS Research and Human Retroviruses, 2009, 25, 1345-1353.	1.1	10
286	HIV Type-1 Group O Infection in Gabon: Low Prevalence Rate But Circulation of Genetically Diverse and Drug-Resistant HIV Type-1 Group O Strains. AIDS Research and Human Retroviruses, 2013, 29, 1085-1090.	1.1	10
287	Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study. Lancet Microbe, The, 2021, 2, e676-e684.	7.3	10
288	Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial). Pharmacoeconomics, 2021, 39, 331-343.	3.3	10

#	Article	IF	CITATIONS
289	Cryptococcus neoformans isolates from Yaound \tilde{A} © human immunodeficiency virus-infected patients exhibited intra-individual genetic diversity and variation in antifungal susceptibility profiles between isolates from the same patient. Journal of Medical Microbiology, 2016, 65, 579-589.	1.8	10
290	First case of mixed infection with Cryptococcus deuterogattii and Cryptococcus neoformans VNI in an Ivorian HIV-positive patient. JMM Case Reports, 2016, 3, e005037.	1.3	10
291	Epidemiology of HIV1 infection among randomized representative Central African populations. Annales De L'Institut Pasteur Virology, 1987, 138, 503-510.	0.5	9
292	Lack of Evidence of Simian Immunodeficiency Virus Infection Among Nonhuman Primates in TaÃ⁻ National Park, Cà te d'Ivoire: Limitations of Noninvasive Methods and SIV Diagnostic Tools for Studies of Primate Retroviruses. International Journal of Primatology, 2011, 32, 288-307.	1.9	9
293	Failure to Detect Simian Immunodeficiency Virus Infection in a Large Cameroonian Cohort with High Non-human Primate Exposure. EcoHealth, 2012, 9, 17-23.	2.0	9
294	Molecular characterization of a new mosaic Simian Immunodeficiency Virus in a naturally infected tantalus monkey (Chlorocebus tantalus) from Cameroon: A challenge to the virus–host co-evolution of SIVagm in African green monkeys. Infection, Genetics and Evolution, 2015, 30, 65-73.	2.3	9
295	Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy. Journal of Antimicrobial Chemotherapy, 2015, 70, 1517-1521.	3.0	9
296	Adherence as a Predictor of Sexual Behaviors in People Living with HIV/AIDS during the First Year of Antiretroviral Therapy in Rural Cameroon: Data from Stratall ANRS 12110/ESTHER Trial. PLoS ONE, 2012, 7, e36118.	2.5	9
297	Impact of HIV Comprehensive Care and Treatment on Serostatus Disclosure among Cameroonian Patients in Rural District Hospitals. PLoS ONE, 2013, 8, e55225.	2.5	9
298	New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon. Bulletin of the World Health Organization, 2015, 93, 521-528.	3.3	9
299	Call for action to secure universal access to ART in developing countries. Lancet, The, 2010, 375, 1693-1694.	13.7	8
300	Morbidity After Antiretroviral Therapy Initiation in HIV-1–Infected Children in West Africa. Pediatric Infectious Disease Journal, 2013, 32, 354-360.	2.0	8
301	Genetic diversity of STLV-2 and interspecies transmission of STLV-3 in wild-living bonobos. Virus Evolution, 2016, 2, vew011.	4.9	8
302	Characterization of HIV-1 Genotypes and Antiretroviral Drug-resistance Mutations among Patients in Burkina Faso. Pakistan Journal of Biological Sciences, 2011, 14, 392-398.	0.5	8
303	High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV). Open Forum Infectious Diseases, 2022, 9, ofac152.	0.9	8
304	Human T-cell lymphotropic virus type I infection and pregnancy: A case-control study and 12-month follow-up of 135 women and their infants. American Journal of Obstetrics and Gynecology, 1991, 165, 1438-1443.	1.3	7
305	Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings. BMC Infectious Diseases, 2012, 12, 147.	2.9	7
306	A novel multiregion hybridization assay reveals high frequency of dual inter-subtype infections among HIV-positive individuals in Cameroon, West Central Africa. Infection, Genetics and Evolution, 2013, 14, 73-82.	2.3	7

#	Article	IF	CITATIONS
307	Development of a checklist of quality indicators for clinical trials in resource-limited countries: The French National Agency for Research on AIDS and Viral Hepatitis (ANRS) experience. Clinical Trials, 2013, 10, 300-318.	1.6	7
308	Susceptibility to Transmitting HIV in Patients Initiating Antiretroviral Therapy in Rural District Hospitals in Cameroon (Stratall ANRS 12110/ESTHER Trial). PLoS ONE, 2013, 8, e62611.	2.5	7
309	Challenges of Antiretroviral Treatment Monitoring in Rural and Remote-Access Regions in Africa. AIDS Research and Human Retroviruses, 2014, 30, 623-625.	1.1	7
310	Non-contiguous finished genome sequence and description of Paenibacillus gorillae sp. nov Standards in Genomic Sciences, 2014, 9, 1031-1045.	1.5	7
311	Phyloepidemiological Analysis Reveals that Viral Divergence Led to the Paucity of Simian Immunodeficiency Virus SIVmus/gsn/mon Infections in Wild Populations. Journal of Virology, 2017, 91, .	3.4	7
312	Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa. Aids, 2020, 34, 783-787.	2.2	7
313	Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. Journal of Medical Virology, $1996, 50, 293-302.$	5.0	7
314	High prevalence of CRF02_AG and many minor resistance-related mutations at the protease gene among HIV-infected treatment-naive immigrants in Madrid. Aids, 2003, 17, 1105-1107.	2.2	7
315	Dynamics of Antibodies to Ebolaviruses in an Eidolon helvum Bat Colony in Cameroon. Viruses, 2022, 14, 560.	3.3	7
316	Short communication Detection of HIV-2 antibodies using five commercial HIV enzyme immunoassays. Aids, 1988, 2, 389-390.	2.2	6
317	WHO clinical criteria-based initiation of antiretroviral therapy: lessons from rural district hospitals in Cameroon with regard to 2009 revised WHO recommendations. Tropical Medicine and International Health, 2010, 15, 580-3.	2.3	6
318	Longâ€ŧerm effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviralâ€naive patients: a 9â€year cohort study in Senegal. Tropical Medicine and International Health, 2011, 16, 217-222.	2.3	6
319	Prediction of HIV Drug Resistance Based on Virologic, Immunologic, Clinical, and/or Adherence Criteria in the Stratall ANRS 12110/ESTHER Trial in Cameroon. Clinical Infectious Diseases, 2013, 57, 604-607.	5.8	6
320	Changes in sexual activity and risk behaviors among PLWHA initiating ART in rural district hospitals in Cameroon – Data from the STRATALL ANRS 12110/ESTHER trial. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2013, 25, 347-355.	1.2	6
321	Virological outcome among HIV-1 infected patients on first-line antiretroviral treatment in semi-rural HIV clinics in Togo. AIDS Research and Therapy, 2015, 12, 38.	1.7	6
322	Genetic diversity and transmission networks of HIV-1 strains among men having sex with men (MSM) in Lomé, Togo. Infection, Genetics and Evolution, 2016, 46, 279-285.	2.3	6
323	ART initiation in an outpatient treatment center in Dakar, Senegal: A retrospective cohort analysis (1998-2015). PLoS ONE, 2018, 13, e0202984.	2.5	6
324	Genetic diversity of simian lentivirus in wild De Brazza's monkeys (Cercopithecus neglectus) in Equatorial Africa. Journal of General Virology, 2010, 91, 1810-1816.	2.9	6

#	Article	IF	CITATIONS
325	Serological Evidence of Ebola Virus Infection in Rural Guinea before the 2014 West African Epidemic Outbreak. American Journal of Tropical Medicine and Hygiene, 2018, 99, 425-427.	1.4	6
326	Human T-cell lymphotropic virus type I infection and pregnancy: A case-control study and 12-month follow-up of 135 women and their infants. American Journal of Obstetrics and Gynecology, 1991, 165, 1438-1443.	1.3	5
327	Hepatitis C virus antibodies in prostitutes in Niger. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 536.	1.8	5
328	Operational research and HIV policy and guidelines: Lessons from a study of patients lost to follow-up from a public antiretroviral treatment program in Cameroon. Journal of Public Health Policy, 2012, 33, 462-477.	2.0	5
329	Assessment of Infections with Microsporidia and Cryptosporidium spp. in Fecal Samples from Wild Primate Populations from Cameroon and Democratic Republic of Congo. International Journal of Primatology, 2015, 36, 227-243.	1.9	5
330	Genetic diversity of the Hwp1gene and HIS3, EF3, CDC3 microsatellites and antifungal susceptibility profiles of Candida albicansisolates from Yaound \tilde{A} \mathbb{C} HIV-infected patients. Medical Mycology, 2016, 55, myw108.	0.7	5
331	Non-contiguous-Finished Genome Sequence and Description of Paenibacillus camerounensis sp. nov Microbial Ecology, 2016, 71, 990-998.	2.8	5
332	Changes in sexual activity and risk behaviors among PLWHA initiating ART in rural district hospitals in Cameroon data from the STRATALL ANRS 12110/ESTHER trial. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2013, 25, 347-55.	1.2	5
333	Added Value of an Anti-Ebola Serology for the Management of Clinically Suspected Ebola Virus Disease Patients Discharged as Negative in an Epidemic Context. Journal of Infectious Diseases, 2022, 226, 352-356.	4.0	5
334	The marriage of science and optimized HIV care in resource-limited settings. Aids, 2008, 22, 2227-2230.	2.2	4
335	Universal health coverage and HIV in resource-constrained countries. Aids, 2013, 27, 2173-2175.	2.2	4
336	Getting pregnant in HIV clinical trials: women's choice and safety needs. The experience from the ANRS12169-2LADY and ANRS12286-MOBIDIP trials. HIV Clinical Trials, 2016, 17, 233-241.	2.0	4
337	Short Communication: Nucleoside Reverse Transcriptase Inhibitors with Reduced Predicted Activity Do Not Impair Second-Line Therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir. AIDS Research and Human Retroviruses, 2018, 34, 477-480.	1.1	4
338	Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS) Tj ETQq0	0 0 rgBT /0	Overlock 10 T
339	HIV Infection Does Not Explain Elevation of Glycated Hemoglobin among Non-Diabetic Patients in Gabon. Clinical Chemistry and Laboratory Medicine, 2000, 38, 673.	2.3	3
340	Origin and Emergence of HIV/AIDS. , 2011, , 689-710.		3
341	Field evaluation of an open and polyvalent universal HIV-1/SIVcpz/SIVgor quantitative RT-PCR assay for HIV-1 viral load monitoring in comparison to Abbott RealTime HIV-1 in Cameroon. Journal of Virological Methods, 2016, 237, 121-126.	2.1	3
342	Origin of HIV/AIDS and risk for ongoing zoonotic transmissions from nonhuman primates to humans. HIV Therapy, 2010, 4, 387-390.	0.6	2

#	Article	IF	CITATIONS
343	Antiretroviral Drugs in Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, e74-e76.	2.1	2
344	Evolution of renal function in African patients initiating second line antiretroviral treatment: findings from the 2LADY-ANRS 12169 trial. Antiviral Therapy, 2016, 22, 195-203.	1.0	2
345	Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal. MedGenMed: Medscape General Medicine, 2007, 9, 7.	0.2	2
346	Seroprevalence of IgG Antibodies Against Multiple Arboviruses in Bats from Cameroon, Guinea, and the Democratic Republic of Congo. Vector-Borne and Zoonotic Diseases, 2022, , .	1.5	2
347	Short Communication : Multiply Spliced <i>env</i> land <i>nef</i> Transcripts of Simian Immunodeficiency Virus from West African Green Monkey (SIVagm-sab). AIDS Research and Human Retroviruses, 1998, 14, 515-519.	1.1	1
348	A simple clinical and paraclinical score predictive of CD4 cell counts below 400/mm3 in HIV-infected adults in Dakar University Hospital, Senegal. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2002, 96, 167-172.	1.8	1
349	HIV laboratory monitoring for effective ART in Africa – Authors' reply. Lancet Infectious Diseases, The, 2012, 12, 430-431.	9.1	1
350	Incidence of infectious morbidity events after second-line antiretroviral therapy initiation in HIV-infected adults in YaoundÃ $ \mathbb Q $, Cameroon. Antiviral Therapy, 2016, 21, 547-552.	1.0	1
351	Full Genome Characterization of a New Simian Immune Deficiency Virus Lineage in a Naturally Infected <i>Cercopithecus ascanius whitesidei <i>i >i >i</i></i>	1.1	1
352	TDF and quantitative ultrasound bone quality in African patients on second line ART, ANRS 12169 2LADY sub-study. PLoS ONE, 2017, 12, e0186686.	2.5	1
353	Comparative Immunovirological and Clinical Responses to Antiretroviral Therapy Between HIV-1 Group O and HIV-1 Group M Infected Patients. Clinical Infectious Diseases, 2019, 70, 1471-1477.	5.8	1
354	High HIV burden and recent transmission chains in rural forest areas in southern Cameroon, where ancestors of HIV-1 have been identified in ape populations. Infection, Genetics and Evolution, 2020, 84, 104358.	2.3	1
355	Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal. Journal of the International AIDS Society, 2007, 9, 7-7.	3.0	O
356	Nonlinear multiple imputation for continuous covariate within semiparametric Cox model: application to HIV data in Senegal. Statistics in Medicine, 2013, 32, 4651-4665.	1.6	0
357	Laboratory monitoring for antiretroviral therapy in low-resource settings. Lancet Infectious Diseases, The, 2013, 13, 739.	9.1	O
358	Reply. American Journal of Ophthalmology, 2017, 181, 180.	3.3	0
359	Implementation and evaluation of a therapeutic patient education programme during a clinical trial in Yaoundé, Cameroon – Trial ANRS-12286/MOBIDIP. Patient Education and Counseling, 2018, 101, 1262-1269.	2.2	О
360	Resistance to Antiretroviral Treatment in Gabon: Need for Implementation of Guidelines on Antiretroviral Therapy Use and HIV-1 Drug Resistance Monitoring in Developing Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 165-168.	2.1	O